US Stocks Mixed; Dollar General Posts Upbeat Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq Composite gaining 50 points, while the Dow and S&P 500 experienced slight declines. Dollar General reported better-than-expected earnings and raised its full-year outlook.
Global Market Trends: European shares were mixed, Asian markets closed unevenly, and U.S. job openings rose significantly in April, exceeding market expectations.
Analyst Views on TRAW
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
